ID: ALA2391285

Max Phase: Preclinical

Molecular Formula: C18H16BrN3O3

Molecular Weight: 402.25

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1cc(Cc2ccoc2)c(=O)n(CC(=O)Nc2ccc(Br)cc2)n1

Standard InChI:  InChI=1S/C18H16BrN3O3/c1-12-8-14(9-13-6-7-25-11-13)18(24)22(21-12)10-17(23)20-16-4-2-15(19)3-5-16/h2-8,11H,9-10H2,1H3,(H,20,23)

Standard InChI Key:  YKRRGFVBYOIVQT-UHFFFAOYSA-N

Associated Targets(Human)

HL-60 67320 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

FML2_HUMAN 519 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

fMet-Leu-Phe receptor 1/2 66 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Formyl peptide receptor 1 1372 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Lipoxin A4 receptor 3472 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 402.25Molecular Weight (Monoisotopic): 401.0375AlogP: 3.14#Rotatable Bonds: 5
Polar Surface Area: 77.13Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 11.69CX Basic pKa: CX LogP: 2.72CX LogD: 2.72
Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.71Np Likeness Score: -1.40

References

1. Giovannoni MP, Schepetkin IA, Cilibrizzi A, Crocetti L, Khlebnikov AI, Dahlgren C, Graziano A, Dal Piaz V, Kirpotina LN, Zerbinati S, Vergelli C, Quinn MT..  (2013)  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.,  64  [PMID:23685570] [10.1016/j.ejmech.2013.03.066]

Source